Get short, timely messages from wendy diller.

Twitter is a rich source of instantly updated information. It's easy to stay updated on an incredibly wide variety of topics. Join today and follow @EBIWendy.

Get updates via SMS by texting follow EBIWendy to 40404 in the United States
Codes for other countries

Country	Code	For customers of
Two-way (sending and receiving) short codes:
Australia	0198089488 Telstra
Canada	21212 (any)
United Kingdom	86444 Vodafone, Orange, 3, O2
Indonesia	89887 AXIS, 3, Telkomsel
Ireland	51210 O2
India	53000 Bharti Airtel, Videocon
Jordan	90903 Zain
New Zealand	8987 Vodafone, Telecom NZ
United States	40404 (any)

EBIWendy

Andreotti@SFB: BMS 2 stay in primary care, but will partner, as w/ Eliquis & 2 diabetes drugs, & will b more sophisticated re doc relations 7:47 AM May 31st via web
Lamberto Andreotti @SFB says not optimistic about Europe, sees need 2 intensify BMS operations in China, Japan, Korea, where growth will be. 7:37 AM May 31st via web
Sun Pharma's New CEO Israel Makov took Teva from$2.5B to $9.4B in 5yrs. See Vikas Dandekar's story in PharmAsiaNews is.gd/1MlTx8 3:54 PM May 30th via web
Where to prioritize resources: India's competitive edge in innovation in oncology now: computational powers, cell therapies, and diagnostics 2:24 PM May 11th via web
Convergence, reverse innovation, funding for Indian start ups are themes of USAICC today, but it's a slow process 1:50 PM May 11th via web
About 10% of Indian population can afford expensive cancer drugs -- Rakesh Jain of MGH @USAICC in Boston. Can India find alternatives? 1:43 PM May 11th via web
@USAIndiaChamberofCommerce meeting in Boston for dynamite speaker line up on US -India R&D innovations & collaborations..stay tuned 8:08 AM May 11th via web
BIOConvention Representing the state of NY, welcome to some new #BIO2012 attendees: @biotuesday @EBIwendy @theresadenmark @amymaxmen 11:10 AM May 9th via HootSuite Retweeted by EBIWendy
U.S. Q1 Lipitor $$ was $383m; Pfizer says successful--share was 2.5x other LOE analogs @5mos. But @what cost? Learnings for Plavix, Diovan? 3:25 PM May 1st via web
How pharma can bridge payor info gap by Easton Associates in Feb. 2012 IN VIVO: bit.ly/IEPjXX. 1:03 PM Apr 30th via web
Correx:16% of 24 Rx reviewed by French HAS bet. 2008-2010 had major benefit, says Easton Ass. More on payor-Rx info gap bit.ly/IEPjXX 12:59 PM Apr 30th via web
Only 10% of 24 new drugs reviewed by French bet. 2008-2010 got high HAS rank & unrestricted reimbursement according to Easton Assoc. study. 12:41 PM Apr 30th via web
More on CATT: Hard to say if very incremental safety-efficacy improvement will help brand growth but insight likely at AVRO this weekend. 12:36 PM Apr 30th via web
2-yr CATT data out, shows near=efficacy for Avastin & Lucentis, monthly doses of either yields bit better vision>as needed. Helps Regeneron? 12:18 PM Apr 30th via web
BioPharmaToday With the excitement this week over Brennan, etc, don't miss this interesting news on biosimilars from Merck bit.ly/ID9WaW 5:05 AM Apr 27th via bitly Retweeted by EBIWendy
With $200M sales in Q12012 NVS says Galvus on track to be $1B drug. Other $1B+ drugs from MNCs that R big ex-US but hit US regulatory snafu? 12:19 PM Apr 25th via web
WW biosimilars sales to reach 50% CAGR, from $0.5B (2011) to $15-$20B (2020). NVS says Sandoz to be #1, unlike competitors not need partners 6:32 AM Apr 25th via web
@LifeSciVC totally agree - but the aim is to try not to give up your lead program, although that's hard if you have a limited pipeline 8:43 AM Apr 13th via web in reply to LifeSciVC
For biotechs looking to raise $$, venture capital cost of capital is 3X more than partnering, says MedImmune's Laufer at PSO 7:20 AM Apr 13th via web
In last 2 years, MRK has done 15 out-licensing deals, all to venture capitalists, expects to do even more in 2012, says Chatterjee. 7:00 AM Apr 13th via web